OptimizeRx price target raised to $23 from $20 at Citizens JMP

Citizens JMP raised the firm’s price target on OptimizeRx (OPRX) to $23 from $20 and keeps an Outperform rating on the shares. The firm is focused on the continued transition of the data component of OptimizeRx’s DAAP offering into a recurring, subscription-based model and the impact of any macro and/or policy-related changes that could affect demand for its solutions, as well as any efforts to regulate more conventional forms of D2C pharma advertising, the analyst tells investors in a research note.